|
Avaliação Intra-Celular Terapies, Inc. (ITCI) DCF
US | Healthcare | Drug Manufacturers - Specialty & Generic | NASDAQ
|
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Intra-Cellular Therapies, Inc. (ITCI) Bundle
Seja você um investidor ou analista, esta calculadora ITCI DCF é o seu recurso preferido para uma avaliação precisa. Pré-carregado com dados reais intra-celulares, Inc., você pode ajustar as previsões e observar os efeitos em tempo real.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 22.5 | 81.7 | 249.1 | 464.4 | 680.9 | 1,247.7 | 2,286.4 | 4,189.9 | 7,678.2 | 14,070.6 |
| Revenue Growth, % | 0 | 262.65 | 204.91 | 86.4 | 46.62 | 83.25 | 83.25 | 83.25 | 83.25 | 83.25 |
| EBITDA | -230.7 | -285.2 | -263.0 | -158.9 | -116.7 | -876.8 | -1,606.7 | -2,944.3 | -5,395.5 | -9,887.5 |
| EBITDA, % | -1023.93 | -348.99 | -105.55 | -34.21 | -17.14 | -70.27 | -70.27 | -70.27 | -70.27 | -70.27 |
| Depreciation | .5 | .5 | .7 | .5 | .0 | 8.4 | 15.4 | 28.3 | 51.8 | 94.9 |
| Depreciation, % | 2.34 | 0.65276 | 0.26331 | 0.1137 | 0 | 0.67475 | 0.67475 | 0.67475 | 0.67475 | 0.67475 |
| EBIT | -231.2 | -285.7 | -263.6 | -159.4 | -116.7 | -877.0 | -1,607.2 | -2,945.2 | -5,397.3 | -9,890.7 |
| EBIT, % | -1026.28 | -349.65 | -105.82 | -34.32 | -17.14 | -70.29 | -70.29 | -70.29 | -70.29 | -70.29 |
| Total Cash | 657.4 | 412.3 | 591.9 | 497.9 | 1,001.1 | 1,247.7 | 2,286.4 | 4,189.9 | 7,678.2 | 14,070.6 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 10.8 | 20.2 | 75.2 | 114.0 | 166.5 | 378.4 | 693.4 | 1,270.7 | 2,328.6 | 4,267.2 |
| Account Receivables, % | 47.78 | 24.67 | 30.18 | 24.55 | 24.45 | 30.33 | 30.33 | 30.33 | 30.33 | 30.33 |
| Inventories | 7.1 | 7.9 | 23.9 | 11.6 | 26.3 | 142.3 | 260.7 | 477.8 | 875.6 | 1,604.5 |
| Inventories, % | 31.32 | 9.73 | 9.6 | 2.51 | 3.86 | 11.4 | 11.4 | 11.4 | 11.4 | 11.4 |
| Accounts Payable | 5.5 | 8.7 | 10.4 | 11.5 | 26.1 | 113.6 | 208.2 | 381.5 | 699.1 | 1,281.1 |
| Accounts Payable, % | 24.42 | 10.64 | 4.17 | 2.47 | 3.83 | 9.1 | 9.1 | 9.1 | 9.1 | 9.1 |
| Capital Expenditure | -.3 | -.3 | -.8 | -.3 | -.3 | -5.0 | -9.1 | -16.8 | -30.7 | -56.3 |
| Capital Expenditure, % | -1.18 | -0.39866 | -0.31228 | -0.05792795 | -0.04729368 | -0.4 | -0.4 | -0.4 | -0.4 | -0.4 |
| Tax Rate, % | -0.63744 | -0.63744 | -0.63744 | -0.63744 | -0.63744 | -0.63744 | -0.63744 | -0.63744 | -0.63744 | -0.63744 |
| EBITAT | -231.2 | -285.7 | -263.6 | -160.1 | -117.5 | -877.0 | -1,607.2 | -2,945.2 | -5,397.3 | -9,890.7 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -243.3 | -292.6 | -333.1 | -185.4 | -170.3 | -1,114.0 | -1,939.8 | -3,554.8 | -6,514.2 | -11,937.5 |
| WACC, % | 7.42 | 7.42 | 7.42 | 7.42 | 7.42 | 7.42 | 7.42 | 7.42 | 7.42 | 7.42 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -18,825.0 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -12,176 | |||||||||
| Terminal Value | -224,683 | |||||||||
| Present Terminal Value | -157,093 | |||||||||
| Enterprise Value | -175,918 | |||||||||
| Net Debt | -290 | |||||||||
| Equity Value | -175,628 | |||||||||
| Diluted Shares Outstanding, MM | 103 | |||||||||
| Equity Value Per Share | -1,702.96 |
What You Will Get
- Real ITCI Financials: Access to historical and projected data for precise valuation.
- Adjustable Inputs: Tailor WACC, tax rates, revenue growth, and capital expenditures to your needs.
- Automatic Calculations: Dynamic computation of intrinsic value and NPV.
- Scenario Analysis: Evaluate various scenarios to assess Intra-Cellular Therapies' future performance.
- Clear and Intuitive Design: Designed for professionals while remaining user-friendly for newcomers.
Key Features
- 🔍 Real-Life ITCI Financials: Pre-filled historical and projected data for Intra-Cellular Therapies, Inc. (ITCI).
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) such as WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate Intra-Cellular Therapies’ intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Intra-Cellular Therapies’ valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- Step 1: Download the Excel file for Intra-Cellular Therapies, Inc. (ITCI).
- Step 2: Review the pre-filled financial data and forecasts for Intra-Cellular Therapies.
- Step 3: Adjust key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model update in real-time as you modify your assumptions.
- Step 5: Evaluate the outputs and leverage the findings for your investment strategies.
Why Choose This Calculator for Intra-Cellular Therapies, Inc. (ITCI)?
- User-Friendly Interface: Tailored for both novices and seasoned professionals.
- Customizable Inputs: Adjust parameters to suit your specific analysis needs.
- Real-Time Valuation: Witness immediate updates to Intra-Cellular Therapies’ valuation as you tweak inputs.
- Preloaded Data: Comes with Intra-Cellular Therapies’ actual financial metrics for swift evaluations.
- Endorsed by Experts: Favored by investors and analysts for making well-informed choices.
Who Should Use This Product?
- Healthcare Investors: Develop comprehensive valuation models for assessing Intra-Cellular Therapies, Inc. (ITCI) stock.
- Pharmaceutical Finance Teams: Evaluate valuation scenarios to inform strategic decisions within the organization.
- Consultants and Advisors: Deliver precise valuation insights for clients interested in Intra-Cellular Therapies, Inc. (ITCI).
- Students and Educators: Utilize real-world data to enhance learning and practice in financial modeling related to the biotech sector.
- Biotech Enthusiasts: Gain insights into how companies like Intra-Cellular Therapies, Inc. (ITCI) are valued in the healthcare market.
What the Template Contains
- Historical Data: Includes Intra-Cellular Therapies, Inc.'s (ITCI) past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate Intra-Cellular Therapies, Inc.'s (ITCI) intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of Intra-Cellular Therapies, Inc.'s (ITCI) financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.